Global Oncology Generic Injectable Drugs Market Insights, Research Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 112

Report ID: 5337

Generic drugs are essential in oncology because some anticancer drugs are only available as generics.
The global Oncology Generic Injectable Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oncology Generic Injectable Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Oncology Generic Injectable Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oncology Generic Injectable Drugs in these regions.
This research report categorizes the global Oncology Generic Injectable Drugs market by top players/brands, region, type and end user. This report also studies the global Oncology Generic Injectable Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Teva Pharmaceutical
Pfizer
AstraZeneca
Roche
Eli Lilly
GlaxoSmithKline
Novartis
Mylan
Natco Pharma

Market size by Product
Large Molecule Drugs
Small Molecule Drugs
Market size by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Oncology Generic Injectable Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Oncology Generic Injectable Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Oncology Generic Injectable Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Oncology Generic Injectable Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Oncology Generic Injectable Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Oncology Generic Injectable Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Oncology Generic Injectable Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Oncology Generic Injectable Drugs Market Size Growth Rate by Product
1.4.2 Large Molecule Drugs
1.4.3 Small Molecule Drugs
1.5 Market by End User
1.5.1 Global Oncology Generic Injectable Drugs Market Size Growth Rate by End User
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Oncology Generic Injectable Drugs Market Size
2.1.1 Global Oncology Generic Injectable Drugs Revenue 2014-2025
2.1.2 Global Oncology Generic Injectable Drugs Sales 2014-2025
2.2 Oncology Generic Injectable Drugs Growth Rate by Regions
2.2.1 Global Oncology Generic Injectable Drugs Sales by Regions
2.2.2 Global Oncology Generic Injectable Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Oncology Generic Injectable Drugs Sales by Manufacturers
3.1.1 Oncology Generic Injectable Drugs Sales by Manufacturers
3.1.2 Oncology Generic Injectable Drugs Sales Market Share by Manufacturers
3.1.3 Global Oncology Generic Injectable Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Oncology Generic Injectable Drugs Revenue by Manufacturers
3.2.1 Oncology Generic Injectable Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Oncology Generic Injectable Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Oncology Generic Injectable Drugs Price by Manufacturers
3.4 Oncology Generic Injectable Drugs Manufacturing Base Distribution, Product Types
3.4.1 Oncology Generic Injectable Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Oncology Generic Injectable Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Oncology Generic Injectable Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Oncology Generic Injectable Drugs Sales by Product
4.2 Global Oncology Generic Injectable Drugs Revenue by Product
4.3 Oncology Generic Injectable Drugs Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Oncology Generic Injectable Drugs Breakdown Data by End User

6 North America
6.1 North America Oncology Generic Injectable Drugs by Countries
6.1.1 North America Oncology Generic Injectable Drugs Sales by Countries
6.1.2 North America Oncology Generic Injectable Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Oncology Generic Injectable Drugs by Product
6.3 North America Oncology Generic Injectable Drugs by End User

7 Europe
7.1 Europe Oncology Generic Injectable Drugs by Countries
7.1.1 Europe Oncology Generic Injectable Drugs Sales by Countries
7.1.2 Europe Oncology Generic Injectable Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Oncology Generic Injectable Drugs by Product
7.3 Europe Oncology Generic Injectable Drugs by End User

8 Asia Pacific
8.1 Asia Pacific Oncology Generic Injectable Drugs by Countries
8.1.1 Asia Pacific Oncology Generic Injectable Drugs Sales by Countries
8.1.2 Asia Pacific Oncology Generic Injectable Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Oncology Generic Injectable Drugs by Product
8.3 Asia Pacific Oncology Generic Injectable Drugs by End User

9 Central & South America
9.1 Central & South America Oncology Generic Injectable Drugs by Countries
9.1.1 Central & South America Oncology Generic Injectable Drugs Sales by Countries
9.1.2 Central & South America Oncology Generic Injectable Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Oncology Generic Injectable Drugs by Product
9.3 Central & South America Oncology Generic Injectable Drugs by End User

10 Middle East and Africa
10.1 Middle East and Africa Oncology Generic Injectable Drugs by Countries
10.1.1 Middle East and Africa Oncology Generic Injectable Drugs Sales by Countries
10.1.2 Middle East and Africa Oncology Generic Injectable Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Oncology Generic Injectable Drugs by Product
10.3 Middle East and Africa Oncology Generic Injectable Drugs by End User

11 Company Profiles
11.1 Teva Pharmaceutical
11.1.1 Teva Pharmaceutical Company Details
11.1.2 Company Business Overview
11.1.3 Teva Pharmaceutical Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Teva Pharmaceutical Oncology Generic Injectable Drugs Products Offered
11.1.5 Teva Pharmaceutical Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Company Business Overview
11.2.3 Pfizer Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Pfizer Oncology Generic Injectable Drugs Products Offered
11.2.5 Pfizer Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 Company Business Overview
11.3.3 AstraZeneca Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 AstraZeneca Oncology Generic Injectable Drugs Products Offered
11.3.5 AstraZeneca Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Company Business Overview
11.4.3 Roche Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Roche Oncology Generic Injectable Drugs Products Offered
11.4.5 Roche Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Company Business Overview
11.5.3 Eli Lilly Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Eli Lilly Oncology Generic Injectable Drugs Products Offered
11.5.5 Eli Lilly Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 Company Business Overview
11.6.3 GlaxoSmithKline Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 GlaxoSmithKline Oncology Generic Injectable Drugs Products Offered
11.6.5 GlaxoSmithKline Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Company Business Overview
11.7.3 Novartis Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Novartis Oncology Generic Injectable Drugs Products Offered
11.7.5 Novartis Recent Development
11.8 Mylan
11.8.1 Mylan Company Details
11.8.2 Company Business Overview
11.8.3 Mylan Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Mylan Oncology Generic Injectable Drugs Products Offered
11.8.5 Mylan Recent Development
11.9 Natco Pharma
11.9.1 Natco Pharma Company Details
11.9.2 Company Business Overview
11.9.3 Natco Pharma Oncology Generic Injectable Drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Natco Pharma Oncology Generic Injectable Drugs Products Offered
11.9.5 Natco Pharma Recent Development

12 Future Forecast
12.1 Oncology Generic Injectable Drugs Market Forecast by Regions
12.1.1 Global Oncology Generic Injectable Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Oncology Generic Injectable Drugs Revenue Forecast by Regions 2019-2025
12.2 Oncology Generic Injectable Drugs Market Forecast by Product
12.2.1 Global Oncology Generic Injectable Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Oncology Generic Injectable Drugs Revenue Forecast by Product 2019-2025
12.3 Oncology Generic Injectable Drugs Market Forecast by End User
12.4 North America Oncology Generic Injectable Drugs Forecast
12.5 Europe Oncology Generic Injectable Drugs Forecast
12.6 Asia Pacific Oncology Generic Injectable Drugs Forecast
12.7 Central & South America Oncology Generic Injectable Drugs Forecast
12.8 Middle East and Africa Oncology Generic Injectable Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Oncology Generic Injectable Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer